Table 1.
Abbreviation of Prepared Batch 1 | Components of Batches 2 | ||
---|---|---|---|
Constitutional Excipient | Cryoprotectant | Bacterial Culture | |
LP_US2_IN | Neusilin® US2 | Inulin | Lactobacillus plantarum R2 Biocenol™ |
LP_US2_SA | Saccharose | ||
LP_US2_ST | Starch 1500® | ||
LP_NS2N_IN | Neusilin® NS2N | Inulin | |
LP_NS2N_SA | Saccharose | ||
LP_NS2N-ST | Starch 1500® | ||
LP_AV_IN | Avicel® PH-101 | Inulin | |
LP_AV_SA | Saccharose | ||
LP_AV_ST | Starch 1500® | ||
LP_IN | – | Inulin | |
LP_SA | Saccharose | ||
LP_ST | Starch 1500® | ||
LP_US2 | Neusilin® US2 | – | |
LP_NS2N | Neusilin® NS2N | ||
LP_AV | Avicel® PH-101 | ||
LP | – | – |
1 Abbreviation of each sample was established by the presence of Lactobacillus plantarum R2 Biocenol™ bacterial culture (LP); constitutional excipient (Neusilin® US2 (US2); Neusilin® NS2N (NS2N); Avicel® PH-101 (AV)); and cryoprotectant employed (inulin (IN); saccharose (SA); starch 1500® (ST)). 2 Each batch consisted of quadruple samples (weighing 20.0 g per sample). Components (bacterial culture: constitutional excipient: cryoprotectant) were always prepared in the preserved ratio of 8:1:1.